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Discussion
Dr FrankW. Sellke (Boston, Mass). TMR was found several years
ago to improve perfusion and function in animals, yet most clinical
trials have had negative or barely positive results. Do you think you
are comparing TMR with no TMR in a clinically relevant model?
We don’t do TMR on patients that don’t have coronary disease or
hypercholesterolemia or other risk factors for vascular disease.
Would you have seen the same changes had you used a model
with endothelial dysfunction and vascular disease?
Dr Atluri. I believe we would have. The goal in this study is that
wewere trying to create a region of myocardial ischemia, a true region
of myocardial hypocontractility. I think the key is that we are looking
at regional dysfunction within our area of interest. Yes, therapy did
create a difference in this model. What we were basically trying to
replicate is not necessarily the global dysfunction but the regional
contractile dysfunction and malperfusion that we are trying to treat.
In human beings, there may be an entire left ventricular region with
endothelial dysfunction and arteriosclerosis, compromising the entire
wall. What we are trying to do is replicate dysfunction in just one re-
gion inwhich the ameroid is placed.We focused our studies on study-
ing this area and also on studying the regional hemodynamic benefits.
Dr Keith B. Allen (Indianapolis, Ind). This was an elegant pre-
sentation, and I enjoyed it. You have shownmicrovascular improve-
ment at the cellular level. I think this explains some of the clinical
findings with regard to the last question, where insensitive tests
such as thallium have been used previously to detect improvement
in perfusion. With a 12% to 15% error rate, it is easy to see why
changes at the cellular level may not necessarily be detected. You
have nicely demonstrated with DNA and cellular analysis that
TMR serves as a biomechanical trigger, with upregulation of the
myocytes surrounding the border zone of the laser channel. We
have hypothesized that this is a fertile area for enhanced angiogen-
esis by the addition of biologic materials, either PRP, stem cells, or
things like VEGF and basic fibroblast growth factor. Do you have
plans to carry on further studies looking at that possibility?
Dr Atluri.We thought this as sort of a two-step process. First, is
TMR usable? I think we have evidence that it is in fact usable. I have
enjoyed reading your articles in the past, and clearly I know that you
believe in the utility of TMR.
I believe the process behind TMR, as you elucidated, is probably
related to inflammation. In this study, inflammation without gross
tissue destruction has been evidenced. For example, you double
TMR channels from 1 to 2 channels/cm2, you get too much destruc-
tion; decrease it, and you don’t have enough inflammation for ther-
apy. The moment you have inflammation, you upregulate cytokines
and DNA transcription factors. After that, you get enhanced micro-
vascular perfusion, which is the key. It is not the development of the
large vessels or the big highways but rather the small microvascula-
ture that enhances perfusion.
The other way to augment that perfusion in addition to upregu-
lating the body’s own reparative system is to enhance angiogenesis
with either additional cytokines or cell transplantation. We are look-
ing into these adjunctive therapies as sort of a second stage of inves-
tigation.
Dr Frank Bowen (Boston, Mass). I have two questions. First,
did you find in the animals that underwent TMR that there was pres-
ervation of global systolic function in terms of preserving left ven-
tricular end-systolic and end-diastolic volumes, leading to increased
cardiac output and global function? Second, given that there are
different energy sources with TMR, do you think that there will
be a difference between a carbon dioxide laser and a Ho:YAG laser?
Dr Atluri. That was the big question we had to answer in decid-
ing on a laser. The three lasers to choose fromwere the excimer laser,
the carbon dioxide laser, and the Ho:YAG laser. The excimer laser is
not commercially available in theUnited States, although it is used in
Europe. Dr Hughes in Journal of the American College of Cardiol-
ogy back in 2002 presented his results in which he basically found
no difference between the excimer laser and sham treatment in terms
of angiogenesis or vascular density. The next decision was between
carbon dioxide and Ho:YAG. Dr Horvath in 2004 published some of
these results. The difference between aHo:YAG laser and carbon di-
oxide laser was marginal; nonetheless, there was enhanced vascular-
ity with a Ho:YAG laser. We theorized from its physical properties
that the Ho:YAG laser generated a greater area of inflammationwith-
out tissue destruction, thereby enhancing angiogenesis. That was our
thought process in picking our laser.
In terms of preservation of ventricular function or ventricular
volumes, if I understood your question correctly, some of the data
that we found in addition (because of time constraints we were un-
able to present all of our data) indicated that there was greater pres-
ervation of ventricular diastolic diameter with TMR. This
approached but did not reach statistical significance.
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